- ►diabetesjournals.org P Raskin, L Klaff, J McGill, SA South, P … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Final HbA 1c values were lower for repaglinide/metformin treatment
than for nateglinide/metformin (7.1 vs. 7.5%). Repaglinide/metformin therapy
showed significantly greater mean reductions of HbA 1c (−1.28 vs. ... Cited by 46 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org V Fonseca, G Grunberger, S Gupta, S Shen, … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—In placebo-treated patients, HbA 1c did not change (Δ = 0.0 ± 0.1%).
In patients randomized to nateglinide, HbA 1c decreased from 8.3 to 7.5% (Δ =
−0.8 ± 0.1%, P < 0.0001 vs. placebo). Target HbA 1c (<7.0%) was achieved ... Cited by 35 - Related articles - BL Direct - All 9 versions
- Free from Publisher J Rosenstock, DR Hassman, RD Madder, SA … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Enrolled patients (n = 150) had received treatment
with diet and exercise in the previous 3 months with HbA 1c >7 and ≤12%.
Patients were randomized to receive monotherapy with repaglinide (n = 76) ... Cited by 60 - Related articles - BL Direct - All 6 versions
P Raskin, J McGill, MF Saad, JM Cappleman, … - Diabetic medicine, 2004 - interscience.wiley.com Methods Enrolled patients (n = 252) were adults having Type 2 diabetes for at
least 1 year, with HbA 1c values > 7.0% after previous monotherapy
(sulphonylurea or metformin, ≥ 50% maximal dose). Prior therapy was ... Cited by 28 - Related articles - BL Direct - All 6 versions
ES Horton, JE Foley, SG Shen, MA Baron - Current Medical Research and Opinion®, 2004 - informahealthcare.com Objective: To assess the efficacy and tolerability of the combination of
nateglinide (120 mg, ac) and metformin (500 mg, tid) as initial treatment in
drug-naïve patients with type 2 diabetes mellitus (T2DM). Research design ... Cited by 19 - Related articles - BL Direct - All 7 versions
MS Rendell, NB Glazer, Z Ye - Journal of diabetes and its complications, 2003 - Elsevier Two separate randomized double-blind trials have reported on the efficacy and
safety of pioglitazone in combination with a sulfonylurea or metformin (Einhorn
et al., 2000 and Kipnes et al., 2001). In one study (Einhorn et al., 2000), ... Cited by 31 - Related articles - All 12 versions
- ►diabetesjournals.org [PDF] MA Baron - Diabetes care, 2003 - Am Diabetes Assoc The authors concluded that when both agents were compared in combination with
metformin, repaglinide lowered fasting plasma glucose and HbA 1c significantly
better than nateglinide and with a similar safety profile. The design of ... Cited by 4 - Related articles - BL Direct - All 5 versions
NN Rudovich, MG Leyck Dieken, H Rochlitz, … - EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY …, 2004 - thieme-connect.com The effects of a combination of repaglinide and metformin on the insulin
secretion pattern and insulin sensitivity were studied in a fixed-dose,
open-label, placebo-controlled cross-over study. Eleven patients with T2 DM ... Cited by 7 - Related articles - BL Direct - All 5 versions
- Free from Publisher J Rosenstock, A Brown, J Fischer, A Jain, T … - Diabetes Care, 1998 - Am Diabetes Assoc T he aim of all strategies for the meta- bolic control of diabetes is to achieve
no rmoglycemia. In patients with type 2 diabetes with milder elevations in
fasting plasma glucose, aninitial attempt to contro l blood glucose is ... Cited by 62 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org J Gerich, P Raskin, L Jean-Louis, D … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—We conducted a randomized, multicenter,
double-masked, 2-year study of 428 drug-naïve patients with type 2 diabetes.
Patients received 120 mg ac nateglinide or 1.25 mg qd glyburide plus 500 mg ... Cited by 43 - Related articles - BL Direct - All 10 versions
